Shares in Allergy Therapeutics plc surged 36 percent Friday on news that the FDA had finally lifted a five-year clinical hold on the development of its Monophosphoryl Lipid A (MPL)-adjuvanted grass pollen allergy vaccine (Grass MATA MPL/ Pollinex Quattro Grass 0.5ml) and had cleared a Phase III protocol for determining the product's efficacy.